

March 17-19, 2026 | Boston, MA

www.novel-conjugates.com

REGISTER BY
DECEMBER 12
TO SAVE UP TO
\$1,000

5th Annual Novel Conjugates Summit

Pioneering Novel Payload & Format Conjugates

Spotlighting Innovation in Novel
Targeting Formats & Payloads to
Enhance Delivery, Overcome Payload
Resistance & Expand Therapeutic Reach

Expert Speakers Include:



Tiffany Thorn
Chief Executive
Officer
**BiVictrix
Therapeutics**



Phil Low
Presidential Scholar
for Drug Discovery
& R.C. Corley
Distinguished
Professor of
Chemistry
Purdue University



Garrett Gross
Director, Research
Innovation & Protein
Engineering
Sutro Biopharma



Sujiet Puthenveetil
Director - Antibody
Drug Conjugates &
Radioconjugates
AstraZeneca



Andrea Geist
Senior Scientist,
PROxAb Shuttle
Merck



Alice Chen
Chief Scientific
Officer
Baylink Biosciences

Proud to Partner With:

MERCK

BSP
PHARMACEUTICALS

NONA
BIOSCIENCES

Lonza

proveo

gbis
BIOMANUFACTURING

+1 617 455 4188 @ info@hansonwade.com

www.novel-conjugates.com

hansonwade

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Dedicated Forum for Showcasing Novel Format & Payload Conjugate

5th Annual
Novel Conjugates Summit
March 17-19, 2026
Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Novel targeting formats and payloads are rapidly reshaping the bioconjugate landscape, with groundbreaking deals between **Merus** and **Biohaven** for bispecific ADCs and **Y-Biologics** and **Ubix Therapeutics** for degrader-antibody conjugates in 2025 alone.

With bispecific ADCs, degrader-antibody conjugates and antibody-oligonucleotide conjugates amongst those leading the charge, the field is racing to unlock greater potency, overcome resistance, and reach new targets with higher specificity.

But as innovation rapidly accelerates across oncology and begins to expand into inflammatory and autoimmune diseases, keeping pace with the breadth of modalities is becoming increasingly complex, let alone staying on top of their progress and key milestones.

The **5th Novel Conjugates Summit** brings clarity to this fast-moving space, with three days dedicated to spotlighting the most exciting advances in novel targeting formats and payloads so you can **return to your team equipped with a breadth of insight into the current approaches being explored**.

Whether you're scouting out the latest modalities from discovery teams or looking for a strategic overview before entering the space, this is the go-to meeting for anyone asking, **"What's next in bioconjugates?"**

Join **100+ discovery and R&D leaders** to explore the key benefits of each novel approach whilst unpicking the crucial considerations in chemistry and biology when moving from concept to clinic, balancing the most valuable technical insight with a broad, cross-modality perspective.

If you're ready to move beyond the traditional and into the future of targeted delivery in oncology and beyond, this is where the next wave begins.

What Last Year's Attendees Have to Say

“I enjoyed the wide spread of the topics, including both new payloads and new protein modalities.”

Pfizer

“Participating in a small conference where you could get to know many of those working in the same or closely related fields was great. It was also great to see a wide range of conjugate formats discussed.”

Prelude Therapeutics

“Great content, high quality of speakers and diverse topics.”

Tallac Therapeutics

Key Benefits of Attending



Discover how degrader-antibody conjugates (DACs) are unlocking new cancer targets and addressing tumour resistance with leading insights from **Merck, Accutar Bio, and Baylink Bioscience**.



Compare small-format, peptide, and multispecific targeting formats to optimize tumor penetration and unlock new indications with **Antikor, K2B Therapeutics, and TwoStep Therapeutics**.



Explore differentiated approaches to bispecific ADC design and development, and gain clarity on how target selection impacts functional outcomes with **BiVictriX and Valink Therapeutics**.



Uncover how bioconjugates are expanding into immunology, inflammation, and neurology, with sessions from **Silence Therapeutics, Dyne Therapeutics and Synthis Therapeutics**.



Understand investor and partnership priorities directly from business development leaders at **Johnson & Johnson, Takeda, Daiichi Sankyo, and Longwood Fund** to accelerate collaboration and commercialization.

What's New For 2026?

5th Annual
Novel Conjugates Summit
March 17-19, 2026
Boston, MA

Key Sessions Not to Miss



Designing Ligand-Targeted Drugs for Treatment of Cancers, Autoimmune, Infectious & Fibrotic Diseases

Purdue University

1



Targeted PROTAC Delivery: Principles of Crafting PROTAC-ADCs & Self-Assembling PROxAb Shuttles

Merck

2



Conditional Logic-Gated Bispecific ADCs: Harnessing Novel Dual Antigen Fingerprints to Expand Efficacy and Minimize On-Target/Off-Tissue Toxicity

BiVictriX

3



Multispecific Drug Conjugates for Combatting Tumor Heterogeneity & Drug Resistance

TwoStep Therapeutics

4



Immunostimulatory-Cytotoxin Dual-Payload ADCs to Enhance Anti-Tumor Immune Response & Overcome Payload Resistance

Sutro Biopharma

5

New Companies for 2026



Investment & Partnership Panel – Accelerating Innovation in Conjugate Therapeutics



Hear directly from pharma business development leaders and investors from **Merck**, **J&J**, **Takeda**, **Novartis**, and **Longwood Fund** as they reveal what drives deal-making in the bioconjugate.

3

+1 617 455 4188 @ info@hansonwade.com

www.novel-conjugates.com



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your 26+ Expert Speakers

5th Annual
Novel Conjugates Summit
March 17-19, 2026
Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Innovative Biotech



Alice Chen
Chief Scientific Officer
Baylink Biosciences



Arne Scheu
Co-Founder & Chief
Executive Officer
Valink Therapeutics



Caitlyn Miller
CEO & Co-Founder
TwoStep Therapeutics



Dan Shores
Patent Attorney
Rothwell Figg



Dori Thomas - Karyat
Founder & Chief Executive
Officer
Synthis Therapeutics, Inc



Garrett Gross
Director, Research
Innovation & Protein
Engineering
Sutro Biopharma



Joe Nabhan
Chief Scientific Officer
K2B Therapeutics Inc.



Lan Xu
Drug Discovery &
Translational Medicine
Advisor
**Polymed
Biopharmaceuticals**



Lucas Bethge
Vice President & Group
Lead - Oligonucleotide
Chemistry
Silence Therapeutics



Mahendra Deodrain
Chief Executive Officer
Antikor



Michael Alonso
Scientific Co-Founder &
SVP Research
Bolt Biotherapeutics



Tiffany Thorn
Chief Executive Officer
BiVictrix Therapeutics



Wei He
Chief Scientific Officer
Accutar Biotechnology



Irsyad Khairil
Co-Founder & Chief
Technology Officer
Valink Therapeutics



Yu-Shin Hsu
Research Analyst Lead
Beacon



Nicholas Yoder
Executive Director
Dyne Therapeutics

Leading Pharma



Andrea Geist
Senior Scientist
**PROxAb Shuttle
Merck**



Sujiet Puthenveetil
Director - Antibody
Drug Conjugates &
Radioconjugates
AstraZeneca



Betsy Gray
Director
Pfizer

Your 26+ Expert Speakers

5th Annual
Novel Conjugates Summit
March 17-19, 2026
Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Investment & Partnership Executives



Carla Baeur
Director, Search & Evaluation, Business Development & Licensing
Merck



Hong Xin
Senior Director, External Innovation, Search & Evaluation
Johnson & Johnson



Juanjo Cragnolini
Associate Director, Search & Evaluation, Oncology R&D
Takeda Pharmaceutical



Vikas Goyal
Partner, Growth Investments
Longwood Fund



Xiaodong Zhang
Director of Search & Evaluation, Oncology & Haematology
Novartis

Leading Academics



Philip Low
Presidential Scholar for Drug Discovery & R.C. Corley Distinguished Professor of Chemistry
Purdue University

“ I am looking forward to the 4th Novel Conjugates Summit because it offers a unique chance to connect with leaders in the field and discuss the future of innovative conjugate strategies. The summit’s focus on novel approaches and cutting-edge research aligns perfectly with our work at TwoStep Therapeutics. I am eager to share our findings, learn from others, and explore new ideas that could enhance our efforts in developing effective cancer treatments. ”

TwoStep Therapeutics

Pre-Conference Workshop Day

Tuesday, March 17 2025

5th Annual
Novel Conjugates Summit
March 17-19, 2026
Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Check in & Registration

8.00

Workshop A

9.00 - 12.00

Designing Holistically: Aligning Targeting Scaffold & Payload Strategy in Novel Conjugates

This workshop explores how targeting format, payload, and linker choices interact to shape efficacy, safety, and clinical strategy, by bringing together a unique audience across the targeting format and payload landscape to understand where different modalities can complement one another for success.

- Understand how targeting format (monoclonal, bispecific, antibody fragment, peptide) influences payload selection and mechanism of action
- Evaluate whether monoclonal antibodies remain optimal for emerging payloads such as degraders and oligonucleotides
- Compare design trade-offs between bispecific targeting and payload potency, stability, and exposure
- Explore compatibility challenges and linker considerations when combining new payload types with novel scaffolds
- Develop an integrated design framework that connects discovery, chemistry, and translational perspectives

Workshop Leaders



Irsyad Khairil
Co-Founder &
Chief Technology
Officer
**Valink
Therapeutics**

Networking Lunch

12.00

Workshop B

1.00 - 4.00

Designing Linker Technologies & Conjugation Approaches that Support the Unique Properties of Novel Payloads & Targeting Formats

This workshop explores the latest approaches to tuning linker performance and conjugation chemistry for ADCs, degraders, peptides, and oligonucleotide conjugates — helping teams engineer reliable, reproducible constructs that translate successfully to the clinic.

- Exploring linker stability, cleavability, and compatibility with degraders, oligos, and peptides
- Addressing conjugation challenges with non-traditional payloads and formats (e.g. enzymatic vs. chemical conjugation)
- Case studies on linker selection for tissue-specific delivery and overcoming off-target toxicity
- Identify future directions in cleavable, condition-responsive, and bioorthogonal linker systems

Workshop Leaders



Sujiet Puthenveetil
Director - Antibody
Drug Conjugates &
Radioconjugates
AstraZeneca

End Pre-Conference Workshop Day

4.00

Conference Day One

Wednesday, March 18 2026



7.00 Check In & Registration

7.45 Chair's Opening Remarks



Philip Low
Presidential Scholar
for Drug Discovery
& Ralph C. Corley
Distinguished Professor
of Chemistry
Purdue University

8.00 **Designing Ligand-Targeted Drugs for Treatment of Cancers, Autoimmune, Infectious & Fibrotic Diseases**

- Exploring the use of small molecule targeting ligands to deliver attached drugs specifically to diseased cells, thereby improving their potencies and avoiding the unwanted toxicities that occur when they accumulate in healthy cells
- For this purpose, we have designed targeting ligands that are highly specific for distinct cancers, different autoimmune disorders, multiple fibrotic diseases, viruses and virus-infected cells, dysregulated immune cells, bone fractures, metabolically aberrant normal cells (e.g. hepatocytes, adipocytes, etc.) and several other cell types
- Applications of these targeting ligands to the design of precision medicines for imaging and therapy of many diseases will be summarized. Although three FDA-approved drugs from my lab will be briefly mentioned, most of the seminar will be devoted to the design of new drugs about to enter or already undergoing human clinical trials

Harnessing Degradable Antibody Conjugates to Tackle Tumor Resistance & Widen the Therapeutic Index



Andrea Geist
Senior Scientist,
PROxAb Shuttle
Merck

8.30 **Targeted PROTAC Delivery: Principles of Crafting PROTAC-ADCs & Self-Assembling PROxAb Shuttles**

- Summarizing the current technological status of Degradable-ADCs, emphasizing the challenges in their generation
- Introducing the PROxAb Shuttle technology, which has the potential to expedite Degradable-ADC discovery
- Presenting data showcasing the practical application of the PROxAb Shuttle *in vivo*



Alice Chen
Chief Scientific Officer
Baylink Bioscience

9.00 **Exploring Novel Protein Degradable & Maximizing Therapeutic Window in Degradable-Antibody-Conjugates**

- Leveraging targeted protein degradation to expand therapeutic reach
- Differentiated MOA compared to existing ADC payloads
- Designing linkers to maximize therapeutic window



9.30 **Speed Networking**

The ideal opportunity to get face-to-face with many of the brightest minds in bioconjugate development, get to know the current state-of-play in the field and form new connections for important in-depth conversations.



10.15 **Morning Break**



10.30 **Session Reserved for Millipore Sigma**



Lan Xu
Drug Discovery &
Translational Medicine
Advisor
**Polymed
Biopharmaceuticals**

11.00 **Showcasing KRas Degradable-Antibody Conjugates as a Therapeutic Approach for Treating KRas Driven Colorectal Cancer**

- Exploring how KRas degraders offer more complete KRas inhibition compared to small molecule inhibitors
- Showing how KRas degrader-Certuximab conjugate has unique advantages in treating KRas driven colorectal cancer
- Highlighting Polymed's KRas degrader and degrader-antibody conjugates demonstrated preclinical proof-of-concept

Conference Day One

Wednesday, March 18 2026

5th Annual
Novel Conjugates Summit
March 17-19, 2026
Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

11.30 Degradable Antibody–Drug Conjugates (DACs): Redefining Payload Design for Precision-Engineered Biotherapeutics



Wei He
Chief Scientific Officer
Accutar Biotechnology

- Chimeric degraders, by leveraging the ubiquitin–proteasome system, can substantially enhance the potency of traditional small-molecule inhibitors, advancing from sub-micromolar to sub-nanomolar efficacy. This capability significantly broadens the accessible payload target space and enables the precision engineering of novel therapeutic payloads
- DACs exhibit internalization-dependent cellular target degradation and robust inhibition of cell proliferation in vitro, demonstrating a powerful mechanism of action that couples targeted delivery with intracellular protein degradation
- DACs are able to display favorable ADME characteristics, potent in vivo antitumor activity with reduced toxicities, underscoring their potential as next-generation precision therapeutics



12.00 Lunch

Advancing Small-Format Conjugates to Improve Tumor Penetration & Unlock Success in New Indications

1.00 Showcasing A Novel CD47-Targeted Protein Drug Conjugate with Broad Anti-Tumor Activity in Diverse Models



Joe Nabhan
Chief Scientific Officer
K2B Therapeutics Inc.

- Engineering a CD47 ligand as a selective tumor-targeting moiety
- Demonstrating potent in vitro and in vivo efficacy of KBA651 across diverse cancer models
- Evaluating pharmacokinetics and safety to support translational studies

1.30 Improving Delivery Efficiency & Unlocking New Indications Through Antibody- Fragment Conjugates



Mahendra Deodrain
Chief Executive Officer
Antikor

- Antikor's platform for recombinant antibody fragments optimized for developability and payload bioconjugation
- Process for Antibody Fragment Drug Conjugate (FDC) discovery, tailoring the linker-payload
- Update on ANT-045, our lead FDC program for cMET-expressing solid tumours
- An insight into Antikor's follow up projects

2.00 Panel Discussion: Comparing the Benefits & Limitations of a 'Fast In, Fast Out' Approach

- Discussing the impact of small format conjugates on PK profiles
- Discussing how linker selection can impact the overall performance of small format conjugates
- Highlighting their potential vs their pitfalls for tumor types which are resistant to ADCs



Mahendra Deodrain
Chief Executive Officer
Antikor



Joe Nabhan
Chief Scientific Officer
K2B Therapeutics



2.30 Session Reserved for BSP



2.45 Afternoon Break & Scientific Poster Presentation

This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new and beneficial relationships. With an audience of bioconjugate experts looking to stay on top of this new and evolving space, you will have the opportunity to display a poster presenting your own work. Additionally, you will have the chance to review others' posters displaying cutting-edge work from drug discovery right through to exciting clinical trial updates.

Conference Day One

Wednesday, March 18 2026

Differentiating Bispecific ADCs By Unlocking Functional Synergy & Mechanistic Clarity



Arne Scheu
Co-Founder & Chief
Executive Officer
Valink Therapeutics

3.30 Beyond Binary: Unlocking the Potential of Bispecific ADCs

- Smarter Targeting with V-gate: How logic gating enhances selectivity and safety in bsADC development
- Discovery Innovation: Valink's unique approach to identifying synergistic target pairs that unlock superior payload delivery and therapeutic windows
- Pipeline Snapshot: A look at Valink's current development programs and how these breakthroughs are shaping the next generation of conjugate therapies



Tiffany Thorn
Chief Executive Officer
BiVictrix Therapeutics

4.00 Conditional Logic-Gated Bispecific ADCs: Harnessing Novel Dual Antigen Fingerprints to Expand Efficacy & Minimize On-Target/Off-Tissue Toxicity

- Conditional logic-gated bispecific ADCs offer a next-generation strategy for precise tumor targeting and improved efficacy in heterogeneous cancers
- By exploiting unique dual-antigen expression fingerprints, they enable selective payload delivery to malignant cells, enhancing potency while minimizing on-target/off-tissue toxicity
- Highlighting key design principles, preclinical validation, and translational insights demonstrating how logic-gated ADCs can overcome the limitations of conventional ADCs and expand therapeutic opportunities across difficult-to-treat tumors



Caitlyn Miller
CEO & Co-Founder
TwoStep Therapeutics

4.30 Multispecific Drug Conjugates Combat Tumor Heterogeneity & Resistance

- Scientific rationale for TwoStep Therapeutics' multi-specific targeting agent "PIP" and how it enables broad applicability across solid tumors
- Preclinical development of PIP-drug conjugates, their efficacy and safety, and comparison to clinical benchmarks
- Comparing the data from a single vs multi-targeted approach to highlight the rationale of multi-specific targeting

5.00 End of Scientific Program Day One

“The organizer has selected the topics and speakers very thoughtfully, which allowed broad enough but at the same time very focused and engaging conversations among attendees”

Salubris Biotherapeutics

Conference Day Two

Thursday March 19 2026

5th Annual
Novel Conjugates Summit
March 17-19, 2026
Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.00 Check In & Registration

9.00 Investment & Partnership Panel - Accelerating Innovation in Conjugate Therapeutics

Hear directly from VCs and pharma BD leaders on what data packages, formats, and strategies attract investment:

- What pharma wants: therapeutic index, MoA clarity, and early efficacy signals
- Pre-IND vs. Phase I: where investors draw the line on risk
- Collaboration models and platform licensing strategies



Juanjo Cragnolini

Associate Director, Search & Evaluation, Oncology R&D
Takeda Pharmaceutical



Carla Baeur

Director, Search & Evaluation, Business Development & Licensing
Merck



Vikas Goyal

Partner, Growth Investments
Longwood Fund



Hong Xin

Senior Director, External Innovation, Search & Evaluation
Johnson & Johnson



Xiaodong Zhang

Director of Search & Evaluation, Oncology & Haematology
Novartis



Dan Shores

Patent Attorney
Rothwell Figg

10.00 Navigating the ADC Patent Landscape: Strategic Approaches to Taking Advantage of Key ADC Patent Expirations & Building ADC Patent Assets With & Without Traditional Payloads

- Analyzing the implications of traditional payload patent expiration on ADC development strategy
- Understanding opportunities for medicinal chemistry modifications to create novel IP around off-patent payloads
- Exploring strategic approaches to protecting novel ADC candidates and evaluating potential candidates against the patent landscape



Yu-Shin Hsu

Research Analyst Lead
Beacon

10.30 Deep Diving Into the Next Wave of ADC & XDC Design & Payload Innovation

- Breaking down the exciting landscape of novel drug conjugate design and mechanism of action
- Exploring emerging trends across drug conjugate design and targets
- Spotlighting novel conjugate innovation across multi payload ADCs, bispecific ADCs, and degrader conjugates



11.00 Session Reserved for GBI Bio



11.15 Morning Break & Networking

Beyond Oncology - Advancing Bioconjugates in Immunology, Inflammation & Neurology

12.150 Looking Beyond Oncology: Investigating Development & Delivery of AOCs Against Neuromuscular Disorders

- Exploring the FORCE modular drug delivery approach to enable widespread distribution of AOCs and chemically diverse therapeutic payloads to muscle and the CNS
- Assessing clinical data from DYNE-101 ACHIEVE trial in patients with DM1 and DYNE-251 DELIVER trial against DMD
- Contextualising how the encouraging clinical data and preclinical efficacy in FSHD and Pompe models supports the potential of FORCETM and AOCs to address neuromuscular disorders with high unmet medical needs



Nicholas Yoder

Executive Director
Dyne Therapeutics

12.45 Expanding Bioconjugate Applications into Immunology & Inflammatory Disease

- Applying conjugate technology to autoimmune and fibrotic conditions
- Exploring payload classes with immune-modulating potential
- Understanding translational challenges beyond oncology targets



Lucas Bethge

Vice President & Group Lead - Oligonucleotide Chemistry
Silence Therapeutics



Conference Day Two

Thursday March 19 2026



1.15 Lunch

Exploring Strategies for Unlocking Success with Immune- Stimulating Payloads



Dori Thomas - Karyat
Founder & Chief
Executive Officer
Synthis Therapeutics, Inc

2.15 Novel, Linkable TGF-b Inhibitor Payload Selectively & Safely Blocks Fibrotic Disease & Immune Suppression in Cancer Patients

- Developed first in class non-cytotoxic, linkable TGF-b inhibitor payload to selectively and safely block TGF-b, in an Antibody drug conjugate format
- SYN101 is a first in class immune cell targeted TGF-b therapy that restores immune function in cancer patients
- SYN303 is a myofibroblast targeted TGF-b therapy that blocks fibrosis and inflammation in a wide variety of fibrotic diseases



Garrett Gross
Director, Research
Innovation & Protein
Engineering
Sutro Biopharma

2.45 Dual-Payload ADCs to Enhance Anti-Tumor Immune Response and Overcome Payload Resistance

- Utilizing an innovative cell-free platform to create site-selective, high DAR, novel dual-payload ADCs with favorable pharmacokinetics
- Showcasing dual-payload ADCs with superior preclinical in vitro and in vivo efficacy to overcome acquired single-payload resistance
- Demonstrating an immunostimulatory-cytotoxin dual-payload ADC with enhanced efficacy and therapeutic potential



Michael Alonso
Scientific Co-Founder &
SVP Research
Bolt Biotherapeutics

3.15 BDC-4182: A Claudin 18.2-Targeting ISAC with Significantly Enhanced Immune Activity and Efficacy in Low Antigen Density Models

- Lessons from 1st Generation ISACs
- Preclinical investigation of BDC-4182
- Benefits of TLR7/8 agonism and initial activity vs ADCs with cytotoxic payloads

3.45 Chair's Closing Remarks

4.00 End of Scientific Program Day Two

“ There were many interesting topics, so I learned a lot. This summit brought together key people in this field, so it was also effective in expanding my network ”

Daiichi Sankyo



Expertise Partner - Millipore Sigma

MilliporeSigma is a leading Life Science company, providing solutions as a strategic partner to help advance the promise of life-saving therapies. Our integrated CDMO Services combine our expertise in contract development, manufacturing, and testing from pre-clinical to commercial to accelerate your milestones and breakthrough – with one experienced partner. We offer 15+ years of leading expertise in the conjugation of drug linkers to monoclonal antibodies (mAbs) and facilities specialized for handling highly potent compounds. To fit your ADC manufacturing needs, our joint ADC offering includes a comprehensive processing portfolio from cell culture media to buffers, salts, and stabilizers and from chromatography to TFF equipment, including single-use templates.

www.sigmaaldrich.com



Hosting Partner - Lonza

Lonza is the leading CDMO for bioconjugates, supporting over 70 ADC programs since 2006 and producing more than 300 cGMP batches annually. Our integrated services span from late discovery to commercial manufacturing, leveraging deep expertise in small molecules, mammalian, microbial, and bioconjugate drug candidates. With cutting-edge technologies, including Synaffix's ADC platform, and continued investment in large-scale manufacturing and drug product filling, we help biotechs and pharma companies bring innovative therapies to patients efficiently, safely, and at scale. Contact us and/or visit our website to find out more.

www.lonza.com



Innovation Partner - BSP Pharmaceuticals

BSP Pharmaceuticals S.p. A. is focused on the development and manufacturing of anticancer drugs with high potency and cytotoxic characteristics for the pharmaceuticals industry. BSP has been at the forefront in the fight against cancer since 2006. Innovation is the hallmark of BSP with investments in new technologies and production methods in a high containment plant.

www.bsppharmaceuticals.com



Innovation Partner - GBI Bio

GBI Bio's mission is to eliminate the manufacturing risk for companies developing complex biologic therapeutics by being the pre-eminent provider of high-quality, cost-effective, flexible and timely cGMP compliant manufacturing solutions, from pre-clinical development through commercial product supply. By integrating our services in one location, Goodwin provides a Single Source Solution™ to anticipate and overcome the challenges you face with your biopharmaceutical candidate, whether it be complex proteins such as monoclonal antibodies or a sophisticated Antibody Drug Conjugate (ADC).

www.gbibio.com

Get Involved



Mehmet Gul
Senior Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com



Exhibition Partner - Nona Biosciences

Nona Biosciences is a Boston-based Biotech company specialized in fully human therapeutic antibody technology. Our proprietary Harbour Mice® technology are fully human transgenic mice platforms for either conventional fully human antibody (H2L2) or heavy chain only (HCAb) antibody discovery, engineering, and development. The HCAb platform is fully optimized and clinically validated with global patented protection.

www.nonabio.com



Event Partner - Proveo

Formed in 2015, PROVEO is now a Division of Cerbios- Pharma SA focused on complete supply chain solution for Antibody Drug Conjugates (ADCs).

Thanks to the partnership with AGC Biologics and Oncotec, PROVEO offer best-in-class solutions for the integrated development and cGMP manufacturing of recombinant proteins (incl mAbs), cytotoxic drug-linker payload, conjugation, aseptic fill and lyophilization. Strengths of the three PROVEO partners secure a seamless and low risk ADC supply chain for clinical and commercial projects.

www.proveoadc.com

■ This congress is a great opportunity to meet and share current scientific knowledge with many other scientists and clinicians who work in the field of alternative drug conjugates. It is one of the few congresses that really focuses on new options beyond the ADC ■

Theratechnologies Inc

Get Involved



Mehmet Gul
Senior Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Take the Spotlight & Partner with the 5th Novel Conjugates Summit

5th Annual
Novel Conjugates Summit
March 17-19, 2026
Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Global Platform to Accelerate Partnerships & Position Your Expertise at the Forefront of Emerging Conjugate Therapeutics

As the only event dedicated exclusively to next-generation bioconjugates, this summit provides a unique platform for CDMOs and service providers to connect directly with the innovators leading the future of targeted delivery. With biopharma investment shifting rapidly toward degrader-, oligonucleotide-, and small-format conjugates, demand for specialized development and manufacturing support is soaring. This is your opportunity to **align your brand with the field's most forward-thinking drug developers** and demonstrate how your expertise can accelerate their next-generation conjugate programs

Why Partner?



Generate Qualified Leads & Commercial Opportunities

Meet senior R&D and CMC leaders actively seeking outsourcing and partnership support in conjugation, linker design, analytical characterization, and GMP manufacturing.



Showcase Your Technical Capabilities


Demonstrate your strengths in process optimization, scale-up, and complex conjugation chemistry to an audience navigating new payload classes and scaffold types.




Position Your Brand as a Trusted Bioconjugation Partner

Align your organization with the industry's most innovative companies advancing the next wave of degrader, oligonucleotide, and multispecific conjugates.

Seniority of Attendees*



Types of Companies Attending*



*Statistics taken from 4th Novel Conjugates Summit

Get Involved



Mehmet Gul
Senior Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

 <https://novel-conjugates.com/take-part/register/>

 Tel: +1 617 455 4188

 Email: info@hansonwade.com



DISCOVER how innovative drug developers are approaching bioconjugates with novel targeting formats and non-cytotoxic payloads



BUILD your understanding of target biology, conjugation chemistry and linker design challenges to enhance translation and safety



ENGAGE with investors and pharma search and evaluation directors to understand the landscape of bioconjugate investment

Drug Developers	Register by December 12 & Save Up to \$1,000	On the Door Price
Conference + Workshop Day	\$3,397	\$4,397
Conference Only	\$2,599	\$3,099
Academic & Research Institutes**	Register by December 12 & Save Up to \$1,000	On the Door Price
Conference + Workshop Day	\$2,797	\$3,797
Conference Only	\$2,199	\$2,699
Solution & Service Providers	Register by December 12 & Save Up to \$1,000	On the Door Price
Conference + Workshop Day	\$4,297	\$5,297
Conference Only	\$3,299	\$3,799

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Hotel Commonwealth

500 Commonwealth Avenue, Boston, Massachusetts, 02215, USA
www.hotelcommonwealth.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom